Kancera AB (OSTO:KAN) ROE % Adjusted to Book Value : -17.20% (As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Kancera AB ROE % Adjusted to Book Value?

Kancera AB's ROE % for the quarter that ended in Sep. 2024 was -57.12%. Kancera AB's PB Ratio for the quarter that ended in Sep. 2024 was 3.32. Kancera AB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -17.20%.

Kancera AB ROE % Adjusted to Book Value Historical Data

The historical data trend for Kancera AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kancera AB ROE % Adjusted to Book Value Chart

Kancera AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-25.66

-8.43

-16.69

-28.96

-10.79

Kancera AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-9.27	-16.69	-33.14	-21.53	-17.20

Competitive Comparison of Kancera AB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Kancera AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kancera AB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kancera AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Kancera AB's ROE % Adjusted to Book Value falls into.

Kancera AB ROE % Adjusted to Book Value Calculation

Kancera AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-83.96%	/	7.78
	=	-10.79%

Kancera AB's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-57.12%	/	3.32
	=	-17.20%

Kancera AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Kancera AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Kancera AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Karolinska Institutet Science Park, Banvaktsvagen 22, Solna, SWE, 171 48

Website

http://www.kancera.com

Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Kancera AB Headlines

No Headlines